Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, provide their support for the use of PARP inhibitors as maintenance therapy in ovarian cancer, and that the optimization of this therapy requires further research to discover the best therapeutic combinations that will be personalized based on patient characteristics. Read More ›

Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, consider the current and future use of immunotherapy, either alone or in combination with other agents such as PARP inhibitors, as first-line maintenance therapy in ovarian cancer. Read More ›

Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, describe the impact that first-line maintenance therapy has on quality of life in patients with ovarian cancer despite adverse events associated with the treatment, and that frequent communication with the healthcare team during maintenance therapy is critical. Read More ›

Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, provide their insights on the occurrence and management of the most common hematologic and nonhematologic adverse events associated with several PARP inhibitors that are used as maintenance therapy in ovarian cancer. Read More ›

Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, discuss the benefits and risks of using combination therapy with a PARP inhibitor and bevacizumab as first-line maintenance therapy in ovarian cancer. Read More ›

Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN and Ali McBride, PharmD, critically review the clinical trial data supporting the use of PARP inhibitors and bevacizumab as first-line maintenance therapy in ovarian cancer. Read More ›

Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN and Ali McBride, PharmD, describe their experiences in the use of niraparib, olaparib and nucaparib as first-line maintenance therapy in Ovarian Cancer. Read More ›

Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, discuss the relative benefits and risks of maintenance therapy in ovarian cancer with bevacizumab versus a PARP inhibitor. Read More ›

Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, deliberate on results from recent clinical trials showing the improvement in progression-free survival after first-line maintenance therapy with PARP inhibitors in patients with ovarian cancer, regardless of HRD status. The experts consider the impact of these data on providing improved treatment options for these patients. Read More ›

Ali McBride, PharmD, and Paula Anastasia, RN, MN, AOCN, discuss how results from germline and somatic HRD testing help provide new options for patients with ovarian cancer. This approach has been a “game changer” in clinical outcomes for these patients. Read More ›

Amina Ahmed, MD, MS, Paula Anastasia, RN, MN, AOCN and Ali McBride, PharmD, MS, discuss the importance of genetic testing in the workup of patients with ovarian cancer, including both germline and somatic testing. The experts consider practice guidelines and results of recent clinical trials and their perspectives on the impact of genetic testing on treatment as well as clinical outcomes. Read More ›

Ali McBride speaks about three new target therapies that have recently come to market. Read More ›

Ali McBride provides some ideas to promoting oral adherence. Read More ›

Ali McBride offers suggestions and ways to help patients with out-of-pocket expenses. Read More ›

Ali McBride talks about patient issues with medication adherence and what payers are doing to ensure compliance. Read More ›

Ali McBride speaks to the challenges of medication adherence, especially in the various settings. Read More ›

Ali McBride discusses medicines that have been on the market for the last few years. Read More ›

This peer-delivered program, brought to you by Takeda, will include a clinical overview of NINLARO and its product attributes. Read More ›

Ali McBride provides an overview of the role of the pharmacist and the importance of working with a broad team of healthcare providers in managing patients on oral oncolytics. Read More ›

Severe hypersensitivity reactions to antineoplastic agents are quite rare, occurring 5% of the time across all agents.¹ Despite this, the impact to the patient can be quite significant, resulting in discomfort and distress, hospitalization, treatment discontinuation, and even death. Unlike most adverse reactions, which often can be predicted, infusion reactions are unexpected and variable. Although rare, nearly every antineoplastic drug has been associated with a hypersensitivity reaction.

Read More ›